| 1 |
34267345 | Itraconazole and rifampicin, as CYP3A modulators but not P-gp modulators, affect the pharmacokinetics of almonertinib and active metabolite HAS-719 in healthy volunteers. | 2022 Apr |
2 |
| 2 |
34417912 | In vitro and clinical investigations to determine the drug-drug interaction potential of entrectinib, a small molecule inhibitor of neurotrophic tyrosine receptor kinase (NTRK). | 2022 Feb |
1 |
| 3 |
34620694 | Pharmacokinetic Drug-Drug Interactions with Drugs Approved by the US Food and Drug Administration in 2020: Mechanistic Understanding and Clinical Recommendations. | 2022 Jan |
2 |
| 4 |
34716565 | Effects of Cytochrome P450 3A4 Induction and Inhibition on the Pharmacokinetics of BI 425809, a Novel Glycine Transporter 1 Inhibitor. | 2022 Jan |
2 |
| 5 |
34989180 | Evaluation of the Pharmacokinetics of Felcisetrag (TAK-954), a 5-HT4 Receptor Agonist, in the Presence and Absence of Itraconazole, a Potent CYP3A4 Inhibitor. | 2022 Feb |
1 |
| 6 |
35165925 | Acalabrutinib CYP3A-mediated drug-drug interactions: Clinical evaluations and physiologically based pharmacokinetic modelling to inform dose adjustment strategy. | 2022 Feb 15 |
1 |
| 7 |
35218073 | Empiric antifungal therapy in patients with cutaneous and subcutaneous phaeohyphomycosis. | 2022 May |
1 |
| 8 |
35246464 | Estimation of Fraction Metabolized by Cytochrome P450 Enzymes Using Long-Term Cocultured Human Hepatocytes. | 2022 May |
1 |
| 9 |
35344780 | Simultaneous determination of almonertinib and its active metabolite HAS-719 in human plasma by LC-MS/MS: Evaluation of pharmacokinetic interactions. | 2022 May 1 |
1 |
| 10 |
35370263 | Effect of Itraconazole and Its Metabolite Hydroxyitraconazole on the Blood Concentrations of Cyclosporine and Tacrolimus in Lung Transplant Recipients. | 2022 |
2 |
| 11 |
35605912 | Effects of itraconazole and rifampicin on the pharmacokinetics and safety of youkenafil, a novel phosphodiesterase type 5 inhibitor, in healthy Chinese subjects. | 2022 May 20 |
1 |
| 12 |
35616006 | Pharmacokinetics of asciminib in the presence of CYP3A or P-gp inhibitors, CYP3A inducers, and acid-reducing agents. | 2022 May 26 |
1 |
| 13 |
32602215 | Effect of Itraconazole, a Potent CYP3A4 Inhibitor, on the Steady-State Pharmacokinetics of Vemurafenib in Patients With BRAFV600 Mutation-Positive Malignancies. | 2021 Jan |
1 |
| 14 |
32928702 | Acute hyperosmolar hyperglycaemic state in cystic fibrosis-related diabetes caused by glucocorticoid and itraconazole interaction. | 2021 Mar |
1 |
| 15 |
33107218 | A Physiologically Based Pharmacokinetic Model to Predict Potential Drug-Drug Interactions and Inform Dosing of Acumapimod, an Oral p38 MAPK Inhibitor. | 2021 Jan |
1 |
| 16 |
33201347 | Serum 4β-hydroxycholesterol increases during fluconazole treatment. | 2021 May |
1 |
| 17 |
33771716 | Evaluation of the pharmacokinetic effects of itraconazole on alflutinib (AST2818): an open-label, single-center, single-sequence, two-period randomized study in healthy volunteers. | 2021 Jul 1 |
1 |
| 18 |
33826998 | Comparison of the inhibitory effects of azole antifungals on cytochrome P450 3A4 genetic variants. | 2021 Jun |
1 |
| 19 |
33964991 | Effect of itraconazole on the pharmacokinetics of faldaprevir in healthy subjects. | 2021 May 1 |
2 |
| 20 |
34049965 | Evaluation of Ipatasertib Interactions with Itraconazole and Coproporphyrin I and III in a Single Drug Interaction Study in Healthy Subjects. | 2021 Aug |
1 |
| 21 |
34140765 | Multiple Administrations of Itraconazole Increase Plasma Exposure to Pyrotinib in Chinese Healthy Adults. | 2021 |
1 |
| 22 |
34145979 | Effects of Itraconazole and Rifampin on the Pharmacokinetics of Mobocertinib (TAK-788), an Oral Epidermal Growth Factor Receptor Inhibitor, in Healthy Volunteers. | 2021 Sep |
2 |
| 23 |
34426442 | Pharmacokinetics, Safety, and Efficacy of Trastuzumab Deruxtecan with Concomitant Ritonavir or Itraconazole in Patients with HER2-Expressing Advanced Solid Tumors. | 2021 Nov 1 |
1 |
| 24 |
34495458 | Physiologically-Based Pharmacokinetic Modelling of Entrectinib Parent and Active Metabolite to Support Regulatory Decision-Making. | 2021 Nov |
1 |
| 25 |
34664792 | In vitro investigations into the roles of CYP450 enzymes and drug transporters in the drug interactions of zanubrutinib, a covalent Bruton's tyrosine kinase inhibitor. | 2021 Dec |
1 |
| 26 |
31287236 | Effects of Strong CYP2C8 or CYP3A Inhibition and CYP3A Induction on the Pharmacokinetics of Brigatinib, an Oral Anaplastic Lymphoma Kinase Inhibitor, in Healthy Volunteers. | 2020 Feb |
1 |
| 27 |
31673875 | Effect of Fluconazole and Itraconazole on the Pharmacokinetics of Erdafitinib in Healthy Adults: A Randomized, Open-Label, Drug-Drug Interaction Study. | 2020 Feb |
1 |
| 28 |
31728714 | The effect of itraconazole on the pharmacokinetics of lorlatinib: results of a phase I, open-label, crossover study in healthy participants. | 2020 Feb |
2 |
| 29 |
31875923 | Effect of rifampin and itraconazole on the pharmacokinetics of zanubrutinib (a Bruton's tyrosine kinase inhibitor) in Asian and non-Asian healthy subjects. | 2020 Feb |
1 |
| 30 |
32080863 | Predicting Clinical Effects of CYP3A4 Modulators on Abemaciclib and Active Metabolites Exposure Using Physiologically Based Pharmacokinetic Modeling. | 2020 Jul |
2 |
| 31 |
32391164 | Simultaneous determination of itraconazole and its CYP3A4-mediated metabolites including N-desalkyl itraconazole in human plasma using liquid chromatography-tandem mass spectrometry and its clinical application. | 2020 |
2 |
| 32 |
32459872 | Pharmacokinetic Drug Interactions of an Orally Available TRH Analog (Rovatirelin) With a CYP3A4/5 and P-Glycoprotein Inhibitor (Itraconazole). | 2020 Oct |
1 |
| 33 |
29320899 | In vitro analysis of itraconazole cis-diastereoisomers inhibition of nine cytochrome P450 enzymes: stereoselective inhibition of CYP3A. | 2019 Jan |
1 |
| 34 |
29989304 | In vivo CYP3A4 activity does not predict the magnitude of interaction between itraconazole and tacrolimus from an extended release formulation. | 2019 Jan |
2 |
| 35 |
30302786 | A phase 1 healthy male volunteer single escalating dose study of the pharmacokinetics and pharmacodynamics of risdiplam (RG7916, RO7034067), a SMN2 splicing modifier. | 2019 Jan |
1 |
| 36 |
30985942 | Application of a physiologically based pharmacokinetic model for the prediction of mirabegron plasma concentrations in a population with severe renal impairment. | 2019 May |
1 |
| 37 |
31044521 | Evaluation of the Drug-Drug Interaction Potential of Acalabrutinib and Its Active Metabolite, ACP-5862, Using a Physiologically-Based Pharmacokinetic Modeling Approach. | 2019 Jul |
1 |
| 38 |
31172535 | Drug-Drug Interaction Study to Assess the Effect of Cytochrome P450 Inhibition and Induction on the Pharmacokinetics of the Novel Cereblon Modulator Avadomide (CC-122) in Healthy Adult Subjects. | 2019 Dec |
1 |
| 39 |
31215774 | Recommendations for the Design of Clinical Drug-Drug Interaction Studies With Itraconazole Using a Mechanistic Physiologically-Based Pharmacokinetic Model. | 2019 Sep |
4 |
| 40 |
31392364 | Siponimod pharmacokinetics, safety, and tolerability in combination with the potent CYP3A4 inhibitor itraconazole in healthy subjects with different CYP2C9 genotypes. | 2019 Nov |
1 |
| 41 |
28782144 | Syndrome of inappropriate antidiuretic hormone secretion from concomitant use of itraconazole and vindesine. | 2018 Feb |
1 |
| 42 |
30068519 | Physiologically Based Pharmacokinetic Model of Itraconazole and Two of Its Metabolites to Improve the Predictions and the Mechanistic Understanding of CYP3A4 Drug-Drug Interactions. | 2018 Oct |
3 |
| 43 |
30166405 | Relationship between In Vivo CYP3A4 Activity, CYP3A5 Genotype, and Systemic Tacrolimus Metabolite/Parent Drug Ratio in Renal Transplant Recipients and Healthy Volunteers. | 2018 Nov |
1 |
| 44 |
30171694 | CYP3A but not P-gp plays a relevant role in the in vivo intestinal and hepatic clearance of the delta-specific phosphoinositide-3 kinase inhibitor leniolisib. | 2018 Sep |
3 |
| 45 |
30481027 | Novel Tetrazole-Containing Analogues of Itraconazole as Potent Antiangiogenic Agents with Reduced Cytochrome P450 3A4 Inhibition. | 2018 Dec 27 |
3 |
| 46 |
27822915 | Analysis of the variable factors influencing tacrolimus blood concentration during the switch from continuous intravenous infusion to oral administration after allogeneic hematopoietic stem cell transplantation. | 2017 Mar |
1 |
| 47 |
28495568 | Quantitative Analyses of the Influence of Parameters Governing Rate-Determining Process of Hepatic Elimination of Drugs on the Magnitudes of Drug-Drug Interactions via Hepatic OATPs and CYP3A Using Physiologically Based Pharmacokinetic Models. | 2017 Sep |
1 |
| 48 |
28679023 | Notable Drug-Drug Interaction Between Etizolam and Itraconazole in Poor Metabolizers of Cytochrome P450 2C19. | 2017 Nov |
1 |
| 49 |
26668209 | Evaluation of Ketoconazole and Its Alternative Clinical CYP3A4/5 Inhibitors as Inhibitors of Drug Transporters: The In Vitro Effects of Ketoconazole, Ritonavir, Clarithromycin, and Itraconazole on 13 Clinically-Relevant Drug Transporters. | 2016 Mar |
1 |
| 50 |
27225997 | Evaluation of Cytochrome P450 3A4-Mediated Drug-Drug Interaction Potential for Cobimetinib Using Physiologically Based Pharmacokinetic Modeling and Simulation. | 2016 Nov |
1 |